BiotechTube

Tideglusib

Pre-clinicalActive
1 views this week 0 watching💤 Quiet
Interest: 20/100
20
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Congenital Myotonic Dystrophy

Conditions

Congenital Myotonic Dystrophy

Trial Timeline

— → —

NCT ID
NCT07119775

About Tideglusib

Tideglusib is a pre-clinical stage product being developed by AMO Pharma for Congenital Myotonic Dystrophy. The current trial status is active. This product is registered under clinical trial identifier NCT07119775. Target conditions include Congenital Myotonic Dystrophy.

What happened to similar drugs?

5 of 20 similar drugs in Congenital Myotonic Dystrophy were approved

Approved (5) Terminated (0) Active (15)
✅turoctocog alfaNovo NordiskApproved
✅eptacog alfa (activated) + Feiba VHNovo NordiskApproved
✅activated recombinant human factor VIINovo NordiskApproved
✅activated recombinant human factor VII + activated recombinant human factor VII + factor VIIINovo NordiskApproved
✅Lipiodol Ultra Fluid with surgical gluesGuerbetApproved
🔄turoctocog alfa + turoctocog alfaNovo NordiskPhase 3
🔄turoctocog alfa pegolNovo NordiskPhase 3

Hype Score Breakdown

Clinical
3
Activity
12
Company
5
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT07119775Pre-clinicalActive
NCT05004129Phase 2/3Recruiting
NCT02858908Phase 2Completed

Competing Products

20 competing products in Congenital Myotonic Dystrophy

See all competitors
ProductCompanyStageHype Score
Tideglusib + PlaceboAMO PharmaPhase 2/3
28
TideglusibAMO PharmaPhase 2/3
35
EDIT-101Editas MedicinePhase 1/2
18
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
17
SPR001Spruce BiosciencesPhase 2
25
SPR001Spruce BiosciencesPhase 2
25
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
17
TildacerfontSpruce BiosciencesPhase 2
17
KW-3357Kyowa KirinPhase 1
29
Pasireotide 0.6Mg Solution for Injection + Saline SolutionNovartisPhase 2
27
Sandostatine LPNovartisPhase 2
35
mycophenolate mofetilRochePhase 1
29
turoctocog alfa + turoctocog alfaNovo NordiskPhase 3
40
catridecacog + recombinant factor XIIINovo NordiskPhase 1
29
activated recombinant human factor VIINovo NordiskPhase 2
35
turoctocog alfa pegolNovo NordiskPhase 3
40
recombinant factor XIIINovo NordiskPre-clinical
26
activated recombinant human factor VII, long acting + activated recombinant human factor VII, long actingNovo NordiskPhase 1
29
Advate® + turoctocog alfaNovo NordiskPhase 1
29
nonacog beta pegolNovo NordiskPhase 3
40